Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models
Zheng Zhong, Nathan Harmston, Kris C. Wood, Babita Madan, David M. Virshup
Zheng Zhong, Nathan Harmston, Kris C. Wood, Babita Madan, David M. Virshup
View: Text | PDF
Research Article Oncology

A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models

  • Text
  • PDF
Abstract

Wnt signaling regulates the balance between stemness and differentiation in multiple tissues and in cancer. RNF43-mutant pancreatic cancers are dependent on Wnt production, and pharmacologic blockade of the pathway, e.g., by PORCN inhibitors, leads to tumor differentiation. However, primary resistance to these inhibitors has been observed. To elucidate potential mechanisms, we performed in vivo CRISPR screens in PORCN inhibitor–sensitive RNF43-mutant pancreatic cancer xenografts. As expected, genes in the Wnt pathway whose loss conferred drug resistance were identified, including APC, AXIN1, and CTNNBIP1. Unexpectedly, the screen also identified the histone acetyltransferase EP300 (p300), but not its paralog, CREBBP (CBP). We found that EP300 is silenced due to genetic alterations in all the existing RNF43-mutant pancreatic cancer cell lines that are resistant to PORCN inhibitors. Mechanistically, loss of EP300 directly downregulated GATA6 expression, thereby silencing the GATA6-regulated differentiation program and leading to a phenotypic transition from the classical subtype to the dedifferentiated basal-like/squamous subtype of pancreatic cancer. EP300 mutation and loss of GATA6 function bypassed the antidifferentiation activity of Wnt signaling, rendering these cancer cells resistant to Wnt inhibition.

Authors

Zheng Zhong, Nathan Harmston, Kris C. Wood, Babita Madan, David M. Virshup

×

Figure 6

p300 maintains GATA6 expression via activating its promoter and an intronic enhancer.

Options: View larger image (or click on image) Download as PowerPoint
p300 maintains GATA6 expression via activating its promoter and an intro...
(A) The UCSC conservation track (100 vertebrate species), ENCODE p300 ChIP-seq track (upper: K562 cells, ENCSR000EGE; lower: HepG2 cells, ENCSR000BLW), and H3K27Ac ChIP-Seq track (HPAF-II cells, extracted from GSE64557) in the GATA6 locus. The potential intronic enhancer region is highlighted. (B) EP300 knockout diminished H3K27Ac in the GATA6 promoter region and intronic enhancer region. H3K27Ac was assessed by the CUT&RUN assay in HPAF-II NTC, EP300 knockout, and Panc10.05 cells. Data are represented as mean ± SD (n = 3 technical replicates). (C) Schematic representation of the luciferase reporter constructs. The GATA6 promoter region and enhancer region (highlighted in A) were cloned into the pGL4.10(luc2) vector. MCS, multiple cloning site. Luc2 encodes a firefly luciferase. (D) GATA6 intronic enhancer sequence and p300 boosted GATA6 promoter-driven luciferase expression. Dual-luciferase reporter assay using firefly luciferase reporter constructs shown in C and a constitutively expressed Renilla luciferase performed in HEK293 cells (n = 2-3 biological replicates). WT p300 or a p300 mutant harboring inactivating mutations in its HAT domain (p300HAT–) were cotransfected. pro-Luc-en#1/2 are clones with 2 SNVs near a microsatellite site in the enhancer region.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts